Abstract
The efficacy of NeuRecover-SA™ (formerly called Tropamine+™, and TropaGen™) in the treatment of cocaine withdrawal and craving was evaluated at a state psychiatric hospital. This double-blind, placebo-controlled study was conducted in hospitalised patients with a DSM-III-R diagnosis of cocaine dependence. Eight patients received NeuRecover-SA™ and 4 patients received placebo. No significant difference in patient demographics was found. The mean number of abstinent symptoms (± SEM) declined over the first 4 days of treatment, 10.63 ± 1.32 on day 1 vs 4 ± 1.65 on day 4 in the NeuRecover-SA™ group compared with 7.25 ± 2.93 on day 1 vs 4.25 ± 3.61 on day 4 in the placebo group. Cocaine craving in the NeuRecover-SA™ group on day 1 was 7.88 ± 1.22 vs 2.71 ± 1.22 on day 4 and 5 ± 2.89 on day 1 vs 2 ± 1.68 on day 4 in the placebo group. A Mann-Whitney U test showed no statistically significant differences in abstinent symptomatology between or within treatment groups, or treatment effect in the placebo group. However, a significant decrease (p < 0.05) in cocaine craving occurred in the NeuRecover-SA™ group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
